Goldman Sachs
OLMA icon

Goldman Sachs’s Olema Pharmaceuticals OLMA Stock Holding History

Goldman Sachs’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$634K Buy
+42,500
New +$946K ﹤0.01% 5435

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Goldman Sachs's OLMA Position: Q1 2026 in Review

Goldman Sachs increased its Olema Pharmaceuticals (OLMA) stake by 28% in Q1 2026, buying an estimated $5.07M and bringing the position to 1,045,589 shares worth $15.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

Goldman Sachs first reported a position in OLMA in Q4 2020 and has held it in 22 quarters since. The position peaked at $20.4M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Goldman Sachs held 1,045,589 shares of Olema Pharmaceuticals worth $15.6M as of Q1 2026.
  • Goldman Sachs bought 227,700 Olema Pharmaceuticals shares in Q1 2026, an estimated $5.07M.
  • Olema Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2683 holding.
  • Goldman Sachs first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Goldman Sachs's Olema Pharmaceuticals position peaked at $20.4M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.